Kalliopi Keramida

Aug 28, 2024 | onlinelibrary.wiley.com | Kalliopi Keramida |Dimitrios Farmakis |Amina Rakisheva |Carlo Gabriele Tocchetti

Carlo Gabriele Tocchetti Department of Translational Medical Sciences (DISMET), ‘Federico II’ University, Naples, Italy Interdepartmental Center of Clinical and Translational Sciences (CIRCET), ‘Federico II’ University, Naples, Italy Interdepartmental Hypertension Research Center (CIRIAPA), ‘Federico II’ University, Naples, Italy Center for Basic and Clinical Immunology Research (CISI), ‘Federico II’ University, Naples, ItalySearch for more papers by this author

Mar 20, 2024 | onlinelibrary.wiley.com | Kalliopi Keramida |ERIC YANG |Anita Deswal

Corresponding Author Kalliopi Keramida Cardiology Department, General Anti-Cancer Oncological Hospital, Agios Savvas, Athens, Greece Corresponding author. Cardiology Department, General Anti-Cancer Oncological Hospital, Agios Savvas, Aleksandras Av. 171, Athens 11522, Greece. Email: [email protected] for more papers by this author

Jun 22, 2023 | mdpi.com | Alexia Alexandraki |Kalliopi Keramida |Elisavet Papageorgiou |Marina Zacharia

Abstract: Simple SummaryCancer therapy-related cardiac dysfunction (CTRCD) has been an urgent medical issue in patients that receive breast cancer therapies including anthracycline-based chemotherapies and/or targeted anti-HER2 therapies such as trastuzumab. Traditional biomarkers used as standard of care may be useful indicators of cardiac damage but their use to predict the onset of CTRCD lacks reliability.

Jun 7, 2023 | frontiersin.org | Yichan Zhang |Andreas M. Beyer |Kalliopi Keramida |Leilei Cheng

1. Introduction For decades, anticancer therapies, such as anthracyclines, cyclophosphamide and trastuzumab, have found broad applications in hematological malignancies and solid tumors, and greatly benefited many patients. However, cardiac injury is the major adverse effect of anticancer treatment (1–3). Many cancer survivors experience not only congestive heart failure, but also myocardial ischemia, thromboembolism, hypertension and arrhythmias that affect their quality of life (1, 4).

Feb 3, 2023 | radcliffecardiology.com | Kalliopi Keramida |Athanasios Kostoulas

Published content on this site is for information purposes and is not a substitute for professional medical advice. Where views/opinions are expressed, they are those of the author(s) and not of Radcliffe Medical Media. Radcliffe Cardiology is part of Radcliffe Medical Media, an independent publisher and the Radcliffe Group Ltd. It is not affiliated with or is an agent of, the Oxford Heart Centre, the John Radcliffe Hospital or the Oxford University Hospitals NHS Foundation Trust group.